David R. Strayer, Chief Science/Medical Officer at HEMISPHERX BIOPHARMA INC (HEB), bought 9,892 shares at $0.46 ($5K) on 2017-02-16, disclosed to the SEC on 2017-02-21.
Open-market purchase of $5k HEB by Chief Science/Medical Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| HEB | BUY | 2012-05-21 | $13K | — | Filing → |
| HEB | SELL | 2010-06-24 | $28K | — | Filing → |
| HEB | BUY | 2010-06-18 | $134K | — | Filing → |